These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 10477593

  • 1. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
    Smythe JA, Fink PD, Logan GJ, Lees J, Rowe PB, Alexander IE.
    J Immunol; 1999 Sep 15; 163(6):3239-49. PubMed ID: 10477593
    [Abstract] [Full Text] [Related]

  • 2. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
    Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S.
    Cancer Res; 2006 Jan 15; 66(2):1147-54. PubMed ID: 16424052
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Expression of costimulatory molecules CD80 and/or CD86 by a Kaposi's sarcoma tumor cell line induces differential T-cell activation and proliferation.
    Foreman KE, Wrone-Smith T, Krueger AE, Nickoloff BJ.
    Clin Immunol; 1999 Jun 15; 91(3):345-53. PubMed ID: 10370381
    [Abstract] [Full Text] [Related]

  • 8. Exogenous and endogenous antigens are differentially presented by mast cells to CD4+ T lymphocytes.
    Frandji P, Tkaczyk C, Oskeritzian C, David B, Desaymard C, Mécheri S.
    Eur J Immunol; 1996 Oct 15; 26(10):2517-28. PubMed ID: 8898968
    [Abstract] [Full Text] [Related]

  • 9. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
    Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW.
    J Immunol; 1998 Nov 15; 161(10):5268-75. PubMed ID: 9820499
    [Abstract] [Full Text] [Related]

  • 10. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R, Vallera DA.
    J Immunol; 1996 Oct 15; 157(8):3250-9. PubMed ID: 8871619
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells.
    Wolthers KC, Otto SA, Lens SM, Kolbach DN, van Lier RA, Miedema F, Meyaard L.
    Eur J Immunol; 1996 Aug 15; 26(8):1700-6. PubMed ID: 8765009
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of CD86/CD28 and CD40/CD154 pathways in regulating monocyte-derived CD80 expression during their interaction with allogeneic endothelium.
    Wang P, Liu Z, Wu C, Zhu B, Wang Y, Xu H.
    Transplant Proc; 2008 Oct 15; 40(8):2729-33. PubMed ID: 18929847
    [Abstract] [Full Text] [Related]

  • 16. Autoimmunity without diabetes in transgenic mice expressing beta cell-specific CD86, but not CD80: parameters that trigger progression to diabetes.
    Guerder S, Eynon EE, Flavell RA.
    J Immunol; 1998 Sep 01; 161(5):2128-40. PubMed ID: 9725204
    [Abstract] [Full Text] [Related]

  • 17. Host B7-1 and B7-2 costimulatory molecules contribute to the eradication of B7-1-transfected P815 tumor cells via a CD8+ T cell-dependent mechanism.
    La Motte RN, Sharpe AH, Bluestone JA, Mokyr MB.
    J Immunol; 1999 Apr 15; 162(8):4817-23. PubMed ID: 10202025
    [Abstract] [Full Text] [Related]

  • 18. Distinct effects of CD86-mediated costimulation on resting versus activated human CD4+ T cells.
    Rogers NJ, Game DS, Camara NO, Jackson IM, Lombardi G, Lechler RI.
    Eur J Immunol; 2005 Oct 15; 35(10):2909-19. PubMed ID: 16180251
    [Abstract] [Full Text] [Related]

  • 19. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V, Bornes S, Rochaix P, Tilkin AF, Peron JM, Bonnet J, Favre G, Couderc B.
    Cancer Gene Ther; 2000 Dec 15; 7(12):1543-56. PubMed ID: 11228533
    [Abstract] [Full Text] [Related]

  • 20. Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: an important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells.
    Plumas J, Chaperot L, Jacob MC, Molens JP, Giroux C, Sotto JJ, Bensa JC.
    Eur J Immunol; 1995 Dec 15; 25(12):3332-41. PubMed ID: 8566020
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.